<DOC>
	<DOC>NCT00893971</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of a single dose of PT003 compared with single doses of PT001 and PT005, and compared with PT001 plus PT005 delivered together as two separate single doses in healthy subjects.</brief_summary>
	<brief_title>Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Provide signed written informed consent 1855 years of age Healthy subjects confirmed by medical history, physical examination, vital signs, pulmonary function tests, electrocardiogram and clinical laboratory tests Female subjects of childbearing potential who are sexually active must be willing to undergo a pregnancy test and agree to use two forms of contraception Body mass index (BMI) between 18.5 and 30, inclusive Nonsmokers for at least 6 months prior to screening Pulmonary function tests within normal limits Willing to remain at the study center for at least 1224 hours on each test day Venous access in both arms to allow collection of numerous blood samples Women who are pregnant or lactating Clinically significant medical conditions Viral illness within the last 30 days Symptomatic prostatic hypertrophy or bladder neck obstruction Known narrowangle glaucoma History of bowel obstruction Clinically significant abnormal electrocardiogram Positive Hepatitis B surface antigen or positive Hepatitis C antibody Positive screening test for HIV antibodies History of hypersensitivity to any beta2agonists, anticholinergics, or any component of the MDI Known or suspected history of alcohol or drug abuse within the last 2years Greater than normal alcohol consumption Ingestion of any poppy seeds within the 48 hours prior to the screening Ingestion of any poppy seeds within the 48 hours prior to, or any alcohol, xanthines or grapefruitcontaining foods or beverages within the 24 hours prior to, or during, each confinement Positive breath alcohol result Positive urine drug screen Use of any beta2agonists,or anticholinergics prior to the recruitment interview Lower respiratory tract infections requiring antibiotics in the previous 6 weeks Use of any other prescription medication Use of any over the counter product, herbal product, diet aid, hormone supplement Donation &gt; 450 ml of blood within 8 weeks of first treatment dose Clinically significant vital sign abnormality Clinically significant biochemical, hematological or urinalysis abnormality Affiliations with investigator site Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives prior to screening, whichever is longer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>